{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:54Z","timestamp":1792788054114,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PROMISE Fund","award":["PROMISE Fund (BE)"],"award-info":[{"award-number":["PROMISE Fund (BE)"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SE9423N"],"award-info":[{"award-number":["1SE9423N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As new therapies for Duchenne muscular dystrophy (DMD) are entering the market, shared decision making (SDM) will become increasingly important. Therefore, this study aimed to understand (1) Belgian stakeholders\u2019 knowledge and perceptions of SDM in DMD treatment decision making, (2) the current state of SDM implementation in DMD in Belgium, examining the role of all involved parties, and (3) the barriers and facilitators for SDM in DMD in the Belgian context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this qualitative study, semi-structured interviews with the multidisciplinary team (MDT) of individuals with DMD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918) and caregivers thereof (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) were conducted in Belgium. Qualitative data was analyzed thematically using the framework method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most caregivers were unfamiliar with the term SDM, while MDT members were aware of it but struggled to define it consistent with existing literature. Despite acknowledging some drawbacks, participants valued SDM as an important process in DMD care, noting its presence in current practice. However, both MDT members and caregivers sometimes questioned the necessity of SDM due to limited treatment options available. Consequently, decision making predominantly relied on (child) neurologists sharing information and seeking consent from caregivers and individuals with DMD for a proposed treatment. Participants highlighted the important role of the MDT, with each professional contributing its unique expertise to SDM. To reduce existing barriers and enhance the SDM process, participants called for clear and transparent information regarding different treatment options, including clinical trials, and detailed information on how treatments might affect patients\u2019 daily life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified an increased need for easily understandable information, particularly regarding DMD care in general, but also about clinical trials covering new and emerging therapies. Developing specific evidence-based tools could support stakeholders\u2019 understanding of this information, thereby enhancing implementation of the SDM process in DMD care. Further, as the treatment landscape of DMD evolves, it will become increasingly important for patients to be supported by an MDT, as they can provide information on clinical trials (e.g., study coordinators), emotional support (e.g., psychologists, nurses), and decisional guidance (e.g., neurologist).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03555-0","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:43:31Z","timestamp":1741596211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Caregivers and multidisciplinary team members\u2019 perspectives on shared decision making in Duchenne muscular dystrophy: A qualitative study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-6936","authenticated-orcid":false,"given":"Elise","family":"Schoefs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7630-4850","authenticated-orcid":false,"given":"Thomas","family":"Desmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Lerinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-575X","authenticated-orcid":false,"given":"Liesbeth De","family":"Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4527-9319","authenticated-orcid":false,"given":"Sam","family":"Geuens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny","family":"Pelicaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-5439","authenticated-orcid":false,"given":"Chantal Van","family":"Audenhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Mommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-4176","authenticated-orcid":false,"given":"Rosanne","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-8298","authenticated-orcid":false,"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"3555_CR1","doi-asserted-by":"crossref","unstructured":"Leigh F, Ferlini A, Biggar D, Bushby K, Finkel R, Morgenroth LP et al. Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy [Internet]. Vol. 142, PEDIATRICS. 2018. Available from: http:\/\/publications.aap.org\/pediatrics\/article-pdf\/142\/Supplement_2\/S5\/905113\/peds_20180333c.pdf","DOI":"10.1542\/peds.2018-0333C"},{"issue":"10","key":"3555_CR2","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168\u201384.","journal-title":"Molecules"},{"key":"3555_CR3","doi-asserted-by":"crossref","unstructured":"Elangkovan N, Dickson G. Gene Therapy for Duchenne muscular dystrophy. Journal of neuromuscular diseases. Volume 8. NLM (Medline); 2021. pp. S303\u201316.","DOI":"10.3233\/JND-210678"},{"key":"3555_CR4","doi-asserted-by":"crossref","unstructured":"Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Journal of Paediatrics and Child Health. Volume 51. Blackwell Publishing; 2015. pp. 759\u201364.","DOI":"10.1111\/jpc.12868"},{"key":"3555_CR5","doi-asserted-by":"crossref","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology. Volume 17. Lancet Publishing Group; 2018. pp. 347\u201361.","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"3555_CR6","unstructured":"Sciensano. The neuromuscular reference centres [Internet]. 2024 [cited 2024 Jun 23]. Available from: https:\/\/www.sciensano.be\/en\/belgian-neuromuscular-diseases-registry-bnmdr\/neuromuscular-reference-centres#:~:text=A%20neuromuscular%20reference%20centre%20is,of%20diagnosis%2C%20treatment%20and%20counseling"},{"key":"3555_CR7","unstructured":"Cosyns M, De Meulemeester E, Devleesschauwer B, BURDEN OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN BELGIUM [Internet]. 2021 [cited 2024 Jun 25]. Available from: https:\/\/www.burden-eu.net\/docs\/ejprd-cosyns.pdf"},{"key":"3555_CR8","doi-asserted-by":"crossref","unstructured":"Osorio AN, Medina Cantillo J, Salas AC, Madruga Garrido M, Vilchez Padilla JJ. NEUROLOG\u00cdA Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy [Internet]. Vol. 34. 2019. Available from: www.elsevier.es\/neurologia","DOI":"10.1016\/j.nrleng.2018.01.001"},{"key":"3555_CR9","doi-asserted-by":"crossref","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Vol. 7, Nature Reviews Disease Primers. Nature Research; 2021.","DOI":"10.1038\/s41572-021-00248-3"},{"key":"3555_CR10","doi-asserted-by":"crossref","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2016.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"3555_CR11","doi-asserted-by":"crossref","unstructured":"Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach. European Journal of Pharmacology. Volume 947. Elsevier B.V.; 2023.","DOI":"10.1016\/j.ejphar.2023.175675"},{"key":"3555_CR12","doi-asserted-by":"crossref","unstructured":"Erkut E, Yokota T. CRISPR therapeutics for Duchenne muscular dystrophy. Volume 23. International Journal of Molecular Sciences. MDPI; 2022.","DOI":"10.20944\/preprints202201.0265.v1"},{"key":"3555_CR13","unstructured":"Food and Drug Administration. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [Internet]. 2016 [cited 2023 Aug 1]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy"},{"key":"3555_CR14","unstructured":"Food and Drug Administration. FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation [Internet]. 2021 [cited 2023 Aug 1]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0"},{"key":"3555_CR15","unstructured":"Food and Drug Administration. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2019 [cited 2023 Aug 1]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation"},{"key":"3555_CR16","unstructured":"Food and Drug Administration. FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation [Internet]. 2020 [cited 2023 Aug 1]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation"},{"key":"3555_CR17","unstructured":"European Medicines Agency. Agamree [Internet]. 2024 [cited 2024 Jun 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/agamree"},{"key":"3555_CR18","unstructured":"Federal agency for medicines and health products. Compassionate use - Medical need [Internet]. [cited 2023 Dec 23]. Available from: https:\/\/www.famhp.be\/en\/human_use\/medicines\/medicines\/research_development\/compassionate_use_medical_need"},{"key":"3555_CR19","unstructured":"EU Clinical Trials Register. Clinical trials for Duchenne Muscular Dystrophy [Internet]. 2023 [cited 2023 Dec 23]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=Duchenne+Muscular+Dystrophy"},{"key":"3555_CR20","doi-asserted-by":"crossref","unstructured":"Geuens S, Willen J, Antonis C, Stegen G, Gielis E, Cuveele E et al. The impact of clinical trial participation on quality of life and psychosocial well-being in children with Duchenne muscular dystrophy and their parents. Neuromuscul Disord. 2023;33(11).","DOI":"10.1016\/j.nmd.2023.10.011"},{"key":"3555_CR21","doi-asserted-by":"crossref","unstructured":"Stiggelbout AM, Van Der Weijden T, De Wit MPT, Frosch D, L\u00e9gar\u00e9 F, Montori VM et al. Shared decision making: Really putting patients at the centre of healthcare. Vol. 344, BMJ (Online). 2012.","DOI":"10.1136\/bmj.e256"},{"key":"3555_CR22","doi-asserted-by":"crossref","unstructured":"Barry MJ, Edggman-Levitan S. Shared Decision Making-The Pinnacle of Patient-Centered Care. New England Journal of Medicine. 2012.","DOI":"10.1056\/NEJMp1109283"},{"key":"3555_CR23","doi-asserted-by":"crossref","unstructured":"Ba GE, Bch MB, Tilburt J, Montori VM, Elwyn G. The ethical imperative for shared decision-making [Internet]. Vol. 1, European Journal for Person Centered Healthcare. 2012. Available from: http:\/\/www.nrlc.org\/healthcarerationing\/SharedDecisionma","DOI":"10.5750\/ejpch.v1i1.645"},{"key":"3555_CR24","doi-asserted-by":"crossref","unstructured":"van der Horst DEM, Garvelink MM, Bos WJW, Stiggelbout AM, Pieterse AH. For which decisions is Shared decision making considered appropriate?\u2013 a systematic review. Patient Education and Counseling. Volume 106. Elsevier Ireland Ltd; 2023. pp. 3\u201316.","DOI":"10.1016\/j.pec.2022.09.015"},{"key":"3555_CR25","doi-asserted-by":"crossref","unstructured":"Charles C, Gafnv A, Whelan T, SHARED DECISION-MAKING IN, THE MEDICAL ENCOUNTER: WHAT DOES IT MEAN? (OR IT TAKES AT LEAST TWO TO TANGO). 44, Soc Sci Med. 1997.","DOI":"10.1016\/S0277-9536(96)00221-3"},{"key":"3555_CR26","doi-asserted-by":"crossref","unstructured":"Stacey D, L\u00e9gar\u00e9 F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews. Volume 2017. John Wiley and Sons Ltd; 2017.","DOI":"10.1002\/14651858.CD001431.pub5"},{"key":"3555_CR27","doi-asserted-by":"crossref","unstructured":"Elwyn G, Price A, Franco JVA, Gulbrandsen P. The limits of shared decision making. BMJ Evid Based Med. 2022.","DOI":"10.4324\/9781003109945-18"},{"key":"3555_CR28","doi-asserted-by":"crossref","unstructured":"Stacey D, Lewis KB, Smith M, Carley M, Volk R, Douglas EE et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Reviews. 2024;2024(1).","DOI":"10.1002\/14651858.CD001431.pub6"},{"key":"3555_CR29","doi-asserted-by":"crossref","unstructured":"Aubree Shay L, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Medical Decision Making. Volume 35. SAGE Publications Inc.; 2015. pp. 114\u201331.","DOI":"10.1177\/0272989X14551638"},{"issue":"1","key":"3555_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/13561820.2010.490502","volume":"25","author":"F L\u00e9gar\u00e9","year":"2011","unstructured":"L\u00e9gar\u00e9 F, Stacey D, Pouliot S, Gauvin FP, Desroches S, Kryworuchko J, et al. Interprofessionalism and shared decision-making in primary care: a stepwise approach towards a new model. J Interprof Care. 2011;25(1):18\u201325.","journal-title":"J Interprof Care"},{"key":"3555_CR31","doi-asserted-by":"publisher","unstructured":"Hollin IL, Craig BM, Coast J, Beusterien K, Vass C, DiSantostefano R et al. Reporting Formative Qualitative Research to Support the Development of Quantitative Preference Study Protocols and Corresponding Survey Instruments: Guidelines for Authors and Reviewers. Patient [Internet]. 2020;13(1):121\u201336. Available from: https:\/\/doi.org\/10.1007\/s40271-019-00401-x","DOI":"10.1007\/s40271-019-00401-x"},{"issue":"6","key":"3555_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"3555_CR33","doi-asserted-by":"crossref","unstructured":"Gorman GS, Jimenez-Moreno AC, Pinto CA, Levitan B, Whichello C, Dyer C et al. A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project. Wellcome Open Res. 2020;5.","DOI":"10.12688\/wellcomeopenres.16116.1"},{"key":"3555_CR34","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","volume":"27","author":"G Elwyn","year":"2012","unstructured":"Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27:1361\u20137.","journal-title":"J Gen Intern Med"},{"key":"3555_CR35","unstructured":"Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004."},{"key":"3555_CR36","doi-asserted-by":"crossref","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013.","DOI":"10.1186\/1471-2288-13-117"},{"key":"3555_CR37","doi-asserted-by":"crossref","unstructured":"Boland L, Graham ID, L\u00e9gar\u00e9 F, Lewis K, Jull J, Shephard A, et al. Barriers and facilitators of pediatric shared decision-making: a systematic review. Implementation Science. Volume 14. BioMed Central Ltd.; 2019.","DOI":"10.1186\/s13012-018-0851-5"},{"issue":"2","key":"3555_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1542\/peds.2010-0526","volume":"126","author":"AG Fiks","year":"2010","unstructured":"Fiks AG, Localio AR, Alessandrini EA, Asch DA, Guevara JP. Shared decision-making in pediatrics: a national perspective. Pediatrics. 2010;126(2):306\u201314.","journal-title":"Pediatrics"},{"issue":"1","key":"3555_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.socscimed.2009.04.030","volume":"69","author":"O Karnieli-Miller","year":"2009","unstructured":"Karnieli-Miller O, Eisikovits Z. Physician as partner or salesman? Shared decision-making in real-time encounters. Soc Sci Med. 2009;69(1):1\u20138.","journal-title":"Soc Sci Med"},{"key":"3555_CR40","doi-asserted-by":"crossref","unstructured":"Hahlweg P, H\u00e4rter M, Nestoriuc Y, Scholl I. How are decisions made in cancer care? A qualitative study using participant observation of current practice. BMJ Open. 2017;7(9).","DOI":"10.1136\/bmjopen-2017-016360"},{"issue":"1","key":"3555_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pec.2015.07.026","volume":"99","author":"BM Wiering","year":"2016","unstructured":"Wiering BM, Noordman J, Tates K, Zwaanswijk M, Elwyn G, De Bont ESJM, et al. Sharing decisions during diagnostic consultations; an observational study in pediatric oncology. Patient Educ Couns. 2016;99(1):61\u20137.","journal-title":"Patient Educ Couns"},{"key":"3555_CR42","doi-asserted-by":"crossref","unstructured":"Grootens-Wiegers P, Hein IM, van den Broek JM, de Vries MC. Medical decision-making in children and adolescents: Developmental and neuroscientific aspects. Vol. 17, BMC pediatrics. BioMed Central Ltd.; 2017.","DOI":"10.1186\/s12887-017-0869-x"},{"key":"3555_CR43","doi-asserted-by":"crossref","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet Neurology. Volume 17. Lancet Publishing Group; 2018. pp. 251\u201367.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"3555_CR44","doi-asserted-by":"crossref","unstructured":"Chan AHY, Aspden T, Brackley K, Ashmore-Price H, Honey M. What information do patients want about their medicines? An exploration of the perspectives of general medicine inpatients. BMC Health Serv Res. 2020;20(1).","DOI":"10.1186\/s12913-020-05911-1"},{"key":"3555_CR45","doi-asserted-by":"crossref","unstructured":"L\u00e9gar\u00e9 F, Ratt\u00e9 S, Gravel K, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals\u2019 perceptions. 73, Patient Education and Counseling. 2008. pp. 526\u201335.","DOI":"10.1016\/j.pec.2008.07.018"},{"key":"3555_CR46","doi-asserted-by":"crossref","unstructured":"Alsulamy N, Lee A, Thokala P, Alessa T. What influences the implementation of Shared decision making: an Umbrella Review. Patient Education and Counseling. Volume 103. Elsevier Ireland Ltd; 2020. pp. 2400\u20137.","DOI":"10.1016\/j.pec.2020.08.009"},{"issue":"7","key":"3555_CR47","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.pec.2020.12.014","volume":"104","author":"SR S\u00f8ndergaard","year":"2021","unstructured":"S\u00f8ndergaard SR, Madsen PH, Hilberg O, Bechmann T, Jakobsen E, Jensen KM, et al. The impact of shared decision making on time consumption and clinical decisions. A prospective cohort study. Patient Educ Couns. 2021;104(7):1560\u20137.","journal-title":"Patient Educ Couns"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03555-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:43:43Z","timestamp":1741596223000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03555-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3555"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03555-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethical Committee Research UZ\/KU Leuven [Belgium; reference S66893]. All participants provided their informed consent to participate in this study prior to the conduct of the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mieke Mommen works for Pfizer NV, Belgium. At the time of conducting this research Rosanne Janssens was affiliated with KU Leuven, however, at the time of drafting this manuscript, she was employed by Evidera, London, UK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}